Short- and long-term effects of molsidomine retard and molsidomine nonretard on exercise capacity and clinical status in patients with stable angina: A multicenter randomized double-blind crossover placebo-controlled trial

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 2, 1998, Pages 271-276

  Messin, Roger ^a   Karpov, Youri ^b   Baikova, Natalia ^c   Bruhwyler, Jacques ^d   Monseu, Marie Joëlle ^d   Guns, Corry ^d   Géczy, Joseph ^d  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^c Mirgom   (Russian Federation)

^d Therabel Pharma Belgium   (Belgium)

Author keywords

Angina pectoris; Coronary insufficiency; Exercise testing; Extended release formulation; Molsidomine; Myocardial ischemia

Indexed keywords

ISOSORBIDE DINITRATE; MOLSIDOMINE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EXERCISE; EXERCISE TOLERANCE; FEMALE; HEADACHE; HEART RATE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT DEPRESSION; SUBLINGUAL DRUG ADMINISTRATION; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANGINA PECTORIS; DEATH, SUDDEN; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEADACHE; HEMODYNAMIC PROCESSES; HUMANS; ISOSORBIDE DINITRATE; MALE; MIDDLE AGED; MOLSIDOMINE; MYOCARDIAL ISCHEMIA; QUALITY OF LIFE; VASODILATOR AGENTS;

EID: 0031911443     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199802000-00013     Document Type: Article

References (9)

1. Rosenkranz B, Winkelmann BR, Parnham MJ. Clinical pharmacokinetics of molsidomine. Clin Pharmacokinet 1996;30:372-84.
2. Dendorfer A. Pharmakologie der Nitrate und anderer NO-Donatoren. Herz 1996;21:38-49.
3. Géczy J, Bruhwyler J, Bult H, Van Hove C, Herman AG. Pharmacological characterization of SIN-1A/cyclodextrin complexes as new direct nitric oxide donors. Eur Heart J 1996;17:265,1488.
4. Messin R, Boxho G, De Smedt J, Buntinx IM. Acute and chronic effect of molsidomine extended release on exercise capacity in patients with stable angina, a double-blind crossover clinical trial versus placebo. J Cardiovasc Pharmacol 1995;25:558-63.
5. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the clinical investigation of anti-anginal medicinal products in stable angina pectoris. London: The European Agency for the Evaluation of Medicinal Products - Human Medicines Evaluation Unit, 1996.
6. Unger P, Leone A, Staroukine M, Degré S, Berkenboom G. Hemodynamic response to molsidomine in patients with ischemic cardiomyopathy tolerant to isosorbide dinitrate. J Cardiovasc Pharmacol 1991;18:888-94.
7. Unger P, Vachiery JL, de Cannière D, Staroukine M, Berkenboom G. Comparison of the hemodynamic responses to molsidomine and isosorbide dinitrate in congestive heart failure. Am Heart J 1994; 128:557-63.
8. Rudolph W, Dirschinger J. Clinical comparison of nitrates and sydnonimines. Eur Heart J 1991;12:33-41.
9. Lehmann G, Reiniger G, Beyerle A, Zeitler H, Rudolph W. Haemodynamic evaluation of two regimens of molsidomine in patients with chronic congestive heart failure. Eur J Clin Pharmacol 1995; 48:109-14.